AU2020372988A1 - Recombinant CDKL5 proteins, gene therapy and production methods - Google Patents
Recombinant CDKL5 proteins, gene therapy and production methods Download PDFInfo
- Publication number
- AU2020372988A1 AU2020372988A1 AU2020372988A AU2020372988A AU2020372988A1 AU 2020372988 A1 AU2020372988 A1 AU 2020372988A1 AU 2020372988 A AU2020372988 A AU 2020372988A AU 2020372988 A AU2020372988 A AU 2020372988A AU 2020372988 A1 AU2020372988 A1 AU 2020372988A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- cdkl5
- polypeptide
- fusion protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928140P | 2019-10-30 | 2019-10-30 | |
| US201962928134P | 2019-10-30 | 2019-10-30 | |
| US62/928,140 | 2019-10-30 | ||
| US62/928,134 | 2019-10-30 | ||
| US202063090520P | 2020-10-12 | 2020-10-12 | |
| US63/090,520 | 2020-10-12 | ||
| PCT/US2020/058247 WO2021087282A1 (en) | 2019-10-30 | 2020-10-30 | Recombinant cdkl5 proteins, gene therapy and production methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020372988A1 true AU2020372988A1 (en) | 2023-06-01 |
Family
ID=75716480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020372988A Abandoned AU2020372988A1 (en) | 2019-10-30 | 2020-10-30 | Recombinant CDKL5 proteins, gene therapy and production methods |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230043046A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073231A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554267A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220106981A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114901802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020372988A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156506A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202136514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087282A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| KR20240100490A (ko) * | 2021-10-18 | 2024-07-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물 |
| WO2023077143A1 (en) * | 2021-11-01 | 2023-05-04 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| AU2023288029A1 (en) * | 2022-06-21 | 2025-02-13 | Skyline Therapeutics Limited | Recombinant aav for the gene therapy of sma disease |
| CN116377050A (zh) * | 2022-12-16 | 2023-07-04 | 湖南家辉生物技术有限公司 | 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用 |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
| CN118638212B (zh) * | 2024-06-18 | 2025-07-04 | 河北绶肽生物科技有限公司 | 一种烟草表达的重组人源ⅲ型胶原蛋白及其编码基因和制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2435562A1 (en) * | 2009-05-26 | 2012-04-04 | Biolex Therapeutics, Inc. | Compositions and methods for production of aglycosylated plasminogen |
| HRP20181315T1 (hr) * | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| HUE055282T2 (hu) * | 2014-02-28 | 2021-11-29 | Univ Bologna Alma Mater Studiorum | TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása |
| EP3632923A1 (en) * | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US20210268072A1 (en) * | 2016-06-28 | 2021-09-02 | Alma Mater Studiorum - Universitá Di Bologna | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof |
| EP3562494A4 (en) * | 2016-12-30 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS |
| US11938197B2 (en) * | 2017-01-10 | 2024-03-26 | The Sydney Children's Hospitals Network (Randwick And Westmead (Incorporating The Royal Alexandra Hospital For Children) | Polynucleotides and vectors for the expression of transgenes |
| EP4585229A3 (en) * | 2017-11-08 | 2026-01-14 | Novartis AG | Means and method for preparing viral vectors and uses of same |
| CN111936624A (zh) * | 2017-11-30 | 2020-11-13 | 阿米库斯治疗学公司 | Cdkl5表达变体和cdkl5融合蛋白 |
| WO2020191241A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| IT201900008877A1 (it) * | 2019-06-13 | 2020-12-13 | Univ Bologna Alma Mater Studiorum | Nuovi costrutti per terapia genica |
-
2020
- 2020-10-30 WO PCT/US2020/058247 patent/WO2021087282A1/en not_active Ceased
- 2020-10-30 JP JP2022525193A patent/JP2022554267A/ja active Pending
- 2020-10-30 AU AU2020372988A patent/AU2020372988A1/en not_active Abandoned
- 2020-10-30 EP EP20881783.3A patent/EP4073231A4/en not_active Withdrawn
- 2020-10-30 US US17/773,416 patent/US20230043046A1/en active Pending
- 2020-10-30 CN CN202080091287.7A patent/CN114901802A/zh active Pending
- 2020-10-30 CA CA3156506A patent/CA3156506A1/en active Pending
- 2020-10-30 TW TW109137883A patent/TW202136514A/zh unknown
- 2020-10-30 KR KR1020227018110A patent/KR20220106981A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4073231A1 (en) | 2022-10-19 |
| CA3156506A1 (en) | 2021-05-06 |
| TW202136514A (zh) | 2021-10-01 |
| JP2022554267A (ja) | 2022-12-28 |
| EP4073231A4 (en) | 2024-06-05 |
| KR20220106981A (ko) | 2022-08-01 |
| WO2021087282A1 (en) | 2021-05-06 |
| CN114901802A (zh) | 2022-08-12 |
| US20230043046A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021087282A1 (en) | Recombinant cdkl5 proteins, gene therapy and production methods | |
| US20240093229A1 (en) | Importation of mitochondrial protein by an enhanced allotopic approach | |
| US20200299654A1 (en) | Cdkl5 expression variants and cdkl5 fusion proteins | |
| KR102697262B1 (ko) | 표적 진핵세포의 세포질로의 폴리펩타이드 카고의 형질 도입 효과를 향상시키기 위한 폴리펩타이드계 셔틀제, 이의 용도, 방법 및 이에 관련된 키트 | |
| US11104891B2 (en) | Engineered botulinum neurotoxins | |
| US9840542B2 (en) | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells | |
| Marcus et al. | Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells | |
| CA2903933C (en) | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells | |
| US20240025960A1 (en) | Rage proteins for the treatment of fibrosis and dna damage mediated diseases | |
| US20150329609A1 (en) | Chimeric dystrophin proteins to treat dystrophinopathies | |
| US20240050524A1 (en) | Delivery of abeta variants for aggregation inhibition | |
| WO2025038031A1 (en) | Engineered mitochondrion | |
| US20140303093A1 (en) | Micro-utrophin polypeptides and methods | |
| KR102201154B1 (ko) | 폴리글루타메이트-TAT-Cre 융합 단백질의 제조방법 | |
| US20250034232A1 (en) | von Willebrand Factor Proteins for Treating Bleeding Disorders | |
| US20230416315A1 (en) | Prion-fc region fusion protein and use thereof | |
| US20240002459A1 (en) | Granulin Compositions and Uses Related Thereto | |
| Mori et al. | Intercellular trafficking activity of herpes simplex virus US11 gene product in the mouse brain | |
| Risco Quiroz | Development of a Novel Strategy to Treat Spinal Muscular Atrophy | |
| WO2011130618A2 (en) | Compositions and methods for producing glycosylated human pdx-1 protein and methods of use therefore |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 30 MAY 2022 TO 28 FEB 2023 IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN FILED |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 28 FEB 2023 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |